FORGOT YOUR PASSWORD?
MEMBERSHIP REGISTRATION
Mission & Vision

Bioterrorism

Education Resources

References & Links

Board Members

Current ISMR Activities

Recent ISMR Programs









Antimicrobial Drug Resistance (AMDR)

Print this section

Print entire program

     2. Infections and Chronic Diseases



2. Infections and Chronic Diseases

The belief that many chronic diseases are infectious in origin goes back to the mid-19th century, when cancer was studied as a possible infectious disease (Institute of Medicine 2002). In the last 15 years, several chronic disorders have been linked to a virus or microorganism, such as peptic ulcer disease with Helicobacter pylori, human papilloma viruses and cervical cancer, Whipple's disease with Tropheryma whippeli, Lyme arthritis and neuroborreliosis with Borrelia burgdorferi, hepatitis viruses with liver cancer, colon cancer with Streptococcus bovis, and HIV with Kaposi sarcoma (see Appendix C). It has been suggested that the incidence of infection-related cancers is underestimated (de Martel and Franceschi 2009; Yeung et al. 2011). Thus, microorganisms that develop resistance to antibiotic or antiviral drugs might contribute to the burden of increasing incidence of chronic and debilitating diseases.




Previous Section    Next Section   
Table of Contents

ACTIVITY OVERVIEW
INTRODUCTION
SECTION ONE: The global threat of AMDR
SECTION TWO: Understanding AMDR
    1. Etiology and Epidemiology
    2. Incidence and Prevalence of Microbial Resistance
    3. Major AMDR Pathogens
       a. Acinetobacter baumanii
       b. Clostridium difficile
       c. Escherichia coli
       d. HIV/AIDS and Sexually Transmitted Infection
       e. Influenza virus
       f. Malaria (Plasmodium)
       g. Methicillin-resistant Staphylococcus aureus (MRSA)
       h. Streptococcus pneumoniae
       i. Tuberculosis and MDR-TB
       j. Vancomycin-Resistant Enterococcus (VRE)
SECTION THREE: Control and Prevention of AMDR
    1. Implications of Microbial Resistance
    2. Infections and Chronic Diseases
    3. Policies and Best Practices
       a. Antimicrobial Drug Stewardship
       b. Surveillance
       c. Environmental Decontamination
       d. Infection Control
       e. Patient Education
    4. Antibiotic Development Pipeline
SECTION FOUR: Conclusions
REFERENCES
APPENDICES
GLOSSARY
Test Questions
Program Evaluation
Self Assessment


© 2018, International Society of Microbial Resistance    |    Terms of Use & Disclaimer